HighMark Wealth Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History
Bought
Maintained
Sold
HighMark Wealth Management's HTGM Position: Q2 2023 in Review
HighMark Wealth Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2023, closing a stake of 580 shares — an estimated $1.57K sold.
HighMark Wealth Management first reported a position in HTGM in Q4 2019 and held it in 14 quarters. The position peaked at $134K in Q4 2019. 0 funds tracked by Wall St. Rank hold HTGM as of Q2 2023.
- HighMark Wealth Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- HighMark Wealth Management sold 580 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2023, an estimated $1.57K.
- HighMark Wealth Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q4 2019 and held it in 14 quarters.
- HighMark Wealth Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $134K in Q4 2019.
- 0 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2023.
Based on HighMark Wealth Management's 13F filing for Q2 2023, filed 26 Jul 2023.